Eton Pharmaceuticals, Inc. (ETON) acquired exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film from Aquestive Therapeutics for seizure clusters in patients with epilepsy, subject to applicable regulatory approvals. Eton paid Aquestive a $10.0 million upfront license fee and is responsible for up to $47.5 million in aggregate regulatory and commercial milestone payments, plus royalties on annual net sales at a mid-teens percentage rate.
Aquestive will be the exclusive manufacturer and supplier, subject to specified exceptions, under a supply agreement with an initial 20-year term. LIBERVANT has tentative FDA approval for patients ages 2 to 5 and 12 and older; a separate application to add ages 6 to 11 is under FDA review with a March 29, 2027 target action date. Eton anticipates commercial availability in April 2027, subject to final FDA approval. The product has patent protection extending into 2038.
Eton Pharmaceuticals, Inc. Chief Business Officer David Krempa sold 4,166 common shares on October 6, 2026, at a weighted average price of $55.0663 per share; the shares were sold in multiple trades at prices from $54.915 to $55.135. On October 2, 2026, he converted 10,522 restricted stock units into 10,522 common shares, with 21,044 restricted stock units reported after the transaction. The units were from a 42,088-unit grant made October 2, 2024, vesting in four equal annual installments beginning October 2, 2025.
Eton Pharmaceuticals, Inc. officer David Krempa reported a proposed sale of 4,166 common shares, with an aggregate market value of $229,406.21, for October 6, 2026, through Raymond James & Associates. The notice says the sale is to cover RSU vesting and lists 10,522 common shares acquired from the issuer through an RSU vest on October 2, 2026.
Eton Pharmaceuticals, Inc. (ETON) announced U.S. commercial availability of IMPAVIDO (miltefosine) capsules. The company says it has integrated Eton Cares patient support, including a $0 co-pay for eligible commercially insured patients and expanded patient assistance programs.
IMPAVIDO is indicated for adults and adolescents aged at least 12 years and weighing at least 30 kg for specified visceral, cutaneous and mucosal leishmaniasis. Eton is working to expand hospital on-site availability through a consignment inventory stocking program. The product has a boxed warning regarding embryo-fetal toxicity and is contraindicated in pregnancy; females of reproductive potential are advised to use effective contraception during treatment and for five months after therapy.
Eton Pharmaceuticals, Inc. (ETON) director Paul V. Maier reported multiple transactions on 2026-08-28. He exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share and 12,500 shares at $7.31 per share, receiving common stock.
On the same date, he sold an aggregate of 50,000 common shares in open-market transactions: 36,387 shares at a weighted average price of $58.64 (range $58.50–$58.97), 13,485 shares at $60.21 (range $60.00–$61.00), and 128 shares at $61.77 (range $61.10–$61.98).
Eton Pharmaceuticals, Inc. (ETON) director Paul V. Maier exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share and concurrently sold 50,000 shares of common stock on 2026-08-28 in multiple open-market transactions at weighted-average prices between about $58.50 and $61.98 per share. Following the option exercise, the reported option position was reduced to zero.
Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock that Paul W. Maier, identified as a director, plans to sell under Rule 144. The notice covers a proposed sale of 50,000 shares of common stock, expected to be sold through Raymond James & Associates, Inc. on or about 08/28/2026. The shares are to be sold for the account of Paul W. Maier and are indicated as relating to stock options.
Eton Pharmaceuticals, Inc. (ETON) reported insider equity activity by Chief Business Officer David Krempa. On 2026-08-24 he exercised an Employee Stock Option to acquire 25,000 shares of common stock at an exercise price of $7.31 per share, reducing that option position to 70,000 options remaining. The resulting 25,000 common shares were then sold in market transactions at a weighted average price of $65.07 per share, with individual sale prices ranging from $64.88 to $65.57. The option originally granted on 2019-02-20 vested in 48 equal monthly installments and expires on 2029-02-19. The filing indicates these transactions were not made pursuant to a Rule 10b5-1 trading plan.
Eton Pharmaceuticals, Inc. (ETON) has an affiliated officer, David Krempa, filing a Rule 144 notice to sell up to 25,000 shares of common stock through Raymond James & Associates, Inc. The planned sale on 08/24/2026 is tied to a stock option exercise for cash.
During the prior three months, Krempa reported sales of 37,524 shares of Eton common stock on 05/26/2026 for $1,180,201.00 and 19,679 shares on 05/27/2026 for $618,569.00. The shares are listed on Nasdaq, and Raymond James is identified as the broker handling the proposed transaction.
Eton Pharmaceuticals, Inc. (ETON) reported that President & CEO Sean Brynjelsen sold a total of 100,000 shares of common stock in four open-market transactions on August 19–20, 2026. The sales used weighted average prices of $62.65, $62.12, $61.11, and $60.17 per share, each executed in multiple trades within stated price ranges.